Theraclion SA (PA:ALTHER) sells the CE-marked EchoPulse ultrasound device and one-time use EPack skin cooling system to treat benign but troublesome breast fibroadenomas (lumps) and palpable thyroid nodules. EchoPulse leaves no ugly scars and carries zero infection risk. Its innovation, Beamotion, speeds up therapy. US clinical trials are underway with possible marketing from 2019. In 2015, Theraclion sold or leased 12 systems for evaluation, mainly in Germany and Asia. In 2016, management expects to sell at least 20 systems. Cash at 31 August 2015 was €4.7m.
To read the entire report Please click on the pdf File Below